Can a 'Maintenance' drug keep advanced sarcoma at bay?
NCT ID NCT06981637
Summary
This study is for people with advanced soft tissue sarcoma whose cancer has been controlled by initial chemotherapy. It compares two approaches: receiving a maintenance chemotherapy drug (pegylated liposomal doxorubicin) every 4 weeks versus taking a break from treatment with close monitoring. The main goal is to see which strategy better keeps the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital
NOT_YET_RECRUITINGKaohsiung City, Taiwan
Contact
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact
-
Kaohsiung Medical University Chung-Ho Memorial Hospital,
RECRUITINGKaohsiung City, Taiwan
Contact
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Email: •••••@•••••
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taiwan
Contact
-
Tri-Service General Hospital
RECRUITINGTaipei, Taiwan
Contact
Conditions
Explore the condition pages connected to this study.